# DalCor Pharmaceuticals Canada

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dalcor-pharmaceuticals-canada

- Industry: Biotechnology
- Headquarters: Montreal, Canada
- Website: www.dalcorpharma.com
- Total disclosed funding: $180M
- Latest round: Series D (Sep 13, 2023)
- Investors on record: 7

## About

DalCor Pharmaceuticals Canada Inc. is a Canadian biotechnology company focused on developing precision medicine solutions for cardiovascular diseases, notably targeting specific genetic profiles to improve patient outcomes.DalCor Pharmaceuticals Canada Inc. specializes in the development of pharmacogenetic treatments for cardiovascular diseases. Established in 2015 in Montreal, Canada, the company has secured three investment deals to date, with the most recent funding round occurring in September 2023. The company raised USD 80.00 mn in Series D funding from Investissement Québec, along with returning investors including Andes Growth and CTI Life Sciences.DalCor Pharmaceuticals is primarily focused on the development and commercialization of dalcetrapib, a pharmacogenetic precision medicine designed to address cardiovascular disease, particularly for individuals with the AA genotype at the rs1967309 location in the ADCY9 gene. This product aims to reduce the incidence of fatal and non-fatal myocardial infarctions (MI) in patients who have experienced acute coronary syndrome (ACS). Dalcetrapib is currently undergoing evaluation in the Dal-GenE-2 (DAL-302) Phase 3 trial, which involves 2,000 patients and follows promising results from the earlier dal-GenE study. The company also collaborates with Roche Molecular Systems to provide a companion diagnostic test that identifies suitable candidates for dalcetrapib treatment based on their genetic makeup. The target market for this product spans multiple regions, focusing on populations with a high prevalence of the AA genotype, including North America and areas with significant African ancestry.DalCor Pharmaceuticals operates with a revenue model primarily based on partnerships and collaborations regarding its flagship product, dalcetrapib. The company holds exclusive worldwide rights for the development, manufacture, and commercialization of this product, positioning it to generate revenue through sales once it receives regulatory approval. Transactions in this business typically involve B2B arrangements with healthcare providers and institutions administering the treatment to eligible patients identified through the diagnostic test. The structure of these transactions may include licensing agreements and collaborations with pharmaceutical distributors and healthcare networks, facilitating the delivery of dalcetrapib to patients with cardiovascular diseases and specific genetic profiles.In September 2023, DalCor Pharmaceuticals Canada Inc. raised USD 80.00 mn in Series D funding to support its growth initiatives. The company is focused on advancing the development of dalcetrapib and is aiming to expand its market presence into regions with high prevalence of the AA genotype by 2024. The recent funding will be utilized to further the ongoing Phase 3 trial of dalcetrapib and to enhance its capabilities in developing companion diagnostics, thereby broadening its reach to suitable patient populations.

## Funding rounds

- Series D, Sep 13, 2023, $80M — Fonds de Solidarité des Travailleurs du Québec, Investment Quebec, CTI Life Sciences, T&B Pharma Consultoria  GMP, Andes Growth
- Series B, Apr 19, 2016, $100M — Sanderling Ventures, CDPQ, Fonds de Solidarité des Travailleurs du Québec, CTI Life Sciences

## Investors

- Sanderling Ventures (https://capitalatlas.ai/funds/sanderling-ventures) — Series B
- CDPQ — Series B
- Fonds de Solidarité des Travailleurs du Québec — Series B, Series D
- CTI Life Sciences (https://capitalatlas.ai/funds/cti-life-sciences) — Series B, Series D
- Investment Quebec (https://capitalatlas.ai/funds/investment-quebec) — Series D
- T&B Pharma Consultoria  GMP — Series D
- Andes Growth — Series D